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One of the most important discoveries of current era is
that the evasion of immune system is the hallmark of
cancer development.1 The immune system is able to
recognise antigens derived from cancer cells and;
therefore, distinguishes them from their normal counter-
parts to generate a tumor-specific T-cell mediated
immune response. Two inhibitory proteins (inhibitory
checkpoints) have been identified leading to immune
evasion, which include cytotoxic T-lymphocyte associated
protein-4 (CTLA-4) and programmed cell death protein-1
(PD-1) and its ligand (PD-L1).2 Based on these
discoveries, various strategies have been devised to
enhance cancer specific immune response. These
include vaccines (like BCG for superficial urinary bladder
cancer)3, cytokines, adaptive CAR-T cell (chimeric
antigen receptor T-cell), and immune checkpoint
inhibitors (ICIs).4 Among these, ICIs are very much on
therapeutic frontier in the current decade. 
Two types of ICIs have been introduced, which include
Anti-CTLA-4 (like ipilimumab) and Anti-PD-1/PD-L1 (like
nivolumab and pembrolizumab).5 These ICIs have
shown significant survival benefit in broad range of
cancers like melanoma, head and neck cancers, renal
cell and transitional cell cancer, non-small cell lung
cancer and refractory lymphomas.6 Due to exemplary
promising effects by these agents, Food and Drug
Administration (FDA) approved these agents for clinical
use in 2011. ICIs reactivate the immune system and
unleash the T-cells to recognise and kill cancer cells.2
This is demonstrated by heavy T-lymphocytes infiltration
in tumor cells around the necrotic foci.7 These T-cells
have affinity for 18-flourine-deoxyglucose (18-FDG) as
shown by Takayoshi in 20028; and this paved the path of
18-FDG positron emission tomography and computerised
tomography (PET/CT) for imaging response evaluation
to ICIs. Like other therapeutic options used in oncology,
the response to ICIs can be evaluated both on
morphological and metabolic criteria. However, it is
important to understand that response to ICIs is different
from chemotherapeutic and molecularly targeted agents,
as it appears quite early; but delayed appearance is not
uncommon.9 So far various response patterns have
been observed for ICIs, which include profound and
durable tumour shrinkage, pseudo-progression and
hyper-progression.10 It is also important to get
acclimatised about novel immune-related adverse
effects (irAEs), which are also different from
chemotherapeutic or molecularly targeted agents.10
Pseudo-progression is defined as apparent disease
progression with initial increase in tumour size with or
without appearance of new lesions, but without
deterioration of clinical status.11 It is commonly observed
in early phase of treatment and usually followed by
reduction or disappearance of tumour or a stable
disease pattern. This paradox in imaging pattern and
clinical status is caused by recruitment of activated
T-cells, which recognise and kill tumor cells (immune
flare).10 This immune flare is responsible for increase in
tumour size and metabolism, which can be assessed on
anatomical (computerised CT, MRI or ultrasound) and
functional (18-FDG based PET) imaging.10 Pseudo-
progression is seen in about 15% of patients with
melanoma and those on anti-CTLA4 (ipilimumab) and
less common (5%) in other tumours and patients treated
with anti-PD1/anti-PD-L1 (nivolumab).10 Based on the
results of initial trials, recent recommendation is to
continue treatment with ICI followed by a follow-up
imaging at least after 4 weeks, but not later than 8
weeks.10 Pseudo-progression is a challenging situation,
both for reporting physicians and oncologists. So far, no
valid biochemical or imaging marker is available to
confirm pseudo-progression.1 Tumour biopsy is considered
the gold standard, which is usually not practical in many
cases. Some initial studies have shown that the higher
circulating tumour DNA at baseline reduces the
probability of pseudo-progression in due course of
treatment.1 Hyper-progression is defined as increase in
tumour growth after the initiation of treatment with ICIs
by a factor of two.10 It is not clearly known whether it is
caused by tumour behaviour or ICI-induced acceleration
because most of the initial trials did not have control
arms.1 In contrary to pseudo-progression, hyper-
progression is associated with symptomatic deterioration,
more commonly (9-29%), occurs in all types of tumours
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with a lower incidence of appearance of new lesions.1
According to recent recommendations, if hyper-
progression is suspected, ICI should be discontinued, as
it is associated with worst prognosis.1
Like chemotherapy or molecularly targeted agents,
response evaluation criteria in solid tumor (RECIST) is
also used for ICIs response evaluation.9 In 2009,
Wolchok et al., used RECIST 1.1 (unidimensional) and
World Health Organization (WHO) criteria (2-dimentional)
on a small group of patients with melanoma treated with
ipilimumab.7 They observed that using either size-based
criteria, resulted in premature discontinuation of
potentially effective therapy in a small group of patients.
This encouraged them to design first immune-related
response criteria (irRC). They found that 10% of patients
being treated with ICI moved from progressive disease
(PD) as per WHO criteria to partial response (irPR) or
stable disease (irSD) as per irRC  due to compatible
overall survival (OS).7 This was the point when pseudo-
progression was recognised as an established response
to ICIs. This was followed by publication of new immune-
related RECIST (irRECIST) criteria by Nishino et al. in
201312 and another in 2017 by RECIST group as
iRECIST.13 In irRC and irRECIST criteria, new lesion(s)
is incorporated in the sum of measurements while
iRECIST considers it as unconfirmed progressive
disease (iUPD) which becomes confirmed progressive
disease (iCPD) on follow-up.
There are two well established metabolic criteria which
are used in PET/CT imaging.10 First was produced by
European Organization of Research and Treatment of
Cancer (EORTC) in 1999. It uses maximum standardised
uptake value (SUVmax) as semi-quantitative parameter
(maximum single pixel-based value).10 SUVmax is the
most commonly used parameter worldwide due to
convenience in using it despite issue of reproducibility.
EORTC criteria was used for ICI response evaluation in
2015. Second criteria is PET-response evaluation
criteria in solid tumor (PERCIST), published by Richard
Wahl in 2009.14 PERCIST recommends to use SULpeak
(SUV measured for body mass index over a 1 cm region
of interest), which is more reproducible than SUVmax. In
2018, PERCIST was used for response evaluation for
patients having ICIs. In 2017, Cho et al., applied irRC,
RECIST1.1, PERCIST, and EORTC criteria individually
and a newly designed criteria (PECRIT: PET/CT criteria
for early prediction of response to ICI) upon a cohort of
20 melanoma patients.15 They found that diagnostic
accuracy of PECRIT was 95%, which was significantly
higher than other morphological or metabolic criteria.
PECRIT also categorised the patients into clinical benefit
group (CB) for patients with complete metabolic
response (CMR),  partial metabolic response (PMR) or
stable metabolic disease (SMD) with SULpeak >15.5%.
While patients with PD or SMD with SULpeak <15.5%
are included in no clinical benefit (NCB) group.15 In 2018,
Heidelberg group used a modified PERCIST criteria
(PERCIMT: PET response evaluation criteria for
immunotherapy) upon a cohort of 41 melanoma patients
treated with ipilimumab.16 Like PECRIT criteria, they
also categorised patients into clinical benefit (CMR,
PMR,SD) and no clinical benefit (PD) groups. However,
they have emphasised upon using size and number of
new lesions to diagnose PD.16
It is also important for reporting physicians and treating
oncologists to be cognizant of novel immune-related
adverse effects (irAEs) as these are different from
chemotherapy and molecularly targeted agents.10 irAEs
can affect any organ as these are attributed to
autoimmunity and T-cell infiltration. 18-FDG PET/CT
plays an important role in diagnosing irAES due to their
characteristic appearance on interim scan and
resolution after steroid therapy on follow-up scan.9
Patient could have skin rash of variable severity or
diarrhea due to colitis, which is more common with
ipilimumab. Colitis is presented as diffuse 18-FDG
uptake over large bowel in interim scan, which has to be
differentiated from metformin (oral hypoglycemic agent)
induced by correlating with symptoms and drug
history.10 ICI-induced pneumonitis is more common with
nivolumab; and usual presentation is dyspnea with
enhanced 18-FDG uptake over both lungs on interim
scan and resolution after steroid treatment on follow-
up.10 Sarcoid-like reaction is more common with
pembrolizumab and appears as intense 18-FDG uptake
on mediastinal nodes with famous "Lambda Sign".10 ICIs
could also involve pituitary-thyroid-adrenal axis with
thyroiditis being the most common presentation.10 Like
pseudo-progression, irAEs are also considered as
predictors of good response to ICIs.
18-FDG PET/CT is considered more sensitive and
informative than contrast enhanced CT (CECT) in
assessing response to ICIs.9 Each PET/CT report
should have information about type of ICI, number of
cycles and date of last ICI administered.  Report should
also mention clinical symptoms related to irAEs and
presence or absence of concomitant presentation on
interim and follow-up scans. Report must also have a
comment about timing of follow-up scan, which is usually
advised after 2-3 cycles or after 8-9 weeks from current
study. It is important to realise that overall clinical status
of the patient must be communicated to reporting
physician by referring oncologist to distinguish pseudo-
progression or hyper-progression with a high level of
confidence.10
Currently, we have been living in the era of ICIs which
have shown significant survival benefit in various
cancers. ICIs have patterns of response and progression,
which are usually different from chemotherapy and
molecularly targeted agents. Pseudo-progression is an
exception and not a rule, which occurs in <10% cases
and failure to recognise it could result in premature
discontinuation of an effective treatment. This has also
led to the development of new immune-related metabolic
and morphological criteria for response evaluation.
Hyper-progression is more common than pseudo-
progression; and is defined by increase in tumour
burden by a factor of two, which predicts worst prognosis.
Hybrid imaging using 18-FDG PET/CT is a better
modality than CECT for assessment of response to ICIs
and early detection and follow-up of irAEs. Pseudo-
progression  and irAEs are considered predictor of good
response to ICIs. Till date, there is no sensitive and
reliable biomarker available to precisely detect efficacy,
pseudo-progression or hyper-progression in patients
being treated with the ICIs.
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